Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients

AIM: To study population pharmacokinetics and pharmacogenetics of ritonavir boosted atazanavir using exactly recorded drug intake time by MEMS. METHODS: The ANRS134–COPHAR 3 trial was conducted in 35 HIV-infected treatment-naïve patients. Atazanavir (300 mg), ritonavir (100 mg), and tenofovir (300 m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Savic, Radojka M., Barrail-Tran, Aurélie, Duval, Xavier, Nembot, George, Panhard, Xavière, Descamps, Diane, Verstuyft, Céline, Vrijens, Bernard, Taburet, Anne-Marie, Goujard, Cécile, Mentré, France
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3939416/
https://ncbi.nlm.nih.gov/pubmed/23033116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2012.137
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak